Dehaier Medical Systems Ltd. Retains The Equity Group to Provide Investor Relations Services

BEIJING, Feb. 21, 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM) (“Dehaier” or the “Company”), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products, today announced that it has retained The Equity Group Inc. to provide investor relations services. Founded in 1974, The Equity Group is a full service, New York-based investor relations and financial communications firm specializing in micro- through mid-cap public companies.

(Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO )

Mr. Ping Chen, Chairman and Chief Executive Officer of Dehaier Medical stated, “We feel that Dehaier is in a strong position, and adding depth to our investor relations program is essential as we expand our outreach this year. We feel there are multiple opportunities for our branded respiratory and oxygen products both within China and internationally. While we continue to focus on executing our operating plan in what is a very promising time for our business, we also look forward to our partnership with The Equity Group to get our message out to a broader investing audience. The Equity Group has a solid, long-term track record as a respected, experienced, results-driven investor relations firm, and we are delighted that they will assist us in communicating our company’s accomplishments, strategy and outlook to a larger and more diverse group of investment professionals.”

About Dehaier Medical Systems Ltd.

Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), Welch Allyn (USA), HEYER (Germany), Timesco (UK), eVent Medical (US) and JMS (Japan). Dehaier’s technology is based on five patents and five software copyrights; additionally Dehaier has three pending patents, six pending software copyrights and proprietary technology. More information may be found at http://www.chinadhr.com.

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are other than statements of historical facts, including in particular statements about Dehaier’s domestic and international expansion plans and investor relations efforts or any results from such efforts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, implementation of and performance under the joint venture agreement by all parties, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

SOURCE Dehaier Medical Systems Ltd.